Symphogen A/S   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lyngby Denmark (2000)
Status: Acquired by Servier (2020)

Organization Overview

First Clinical Trial
2008
NCT00718692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Symphogen A/S | Symphogen A/S, Denmark

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Colorectal Neoplasms (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 15